CD274 and neoplasm: Consistent with the data from previous studies (31, 32), these results provide further evidence that PD-L1 expression is not a direct indicator of the tumor suppressive activity of immune checkpoint inhibitors, as nivolumab sharply suppressed tumor activity despite the absence of PD-L1 in the tumor.